Shc inhibitors belong to a distinct chemical class of compounds that hold significance due to their intricate role in cellular signaling pathways. These inhibitors target the Shc proteins, which are crucial intermediaries in various signal transduction cascades. Shc proteins, comprising several isoforms, function as adapters in signal transmission from activated cell surface receptors to downstream signaling components within the cell. Their role is pivotal in mediating responses to extracellular stimuli, such as growth factors and cytokines, by conveying signals that govern cell proliferation, differentiation, migration, and survival.
The mechanism of action of Shc inhibitors lies in their ability to impede the interaction between Shc proteins and upstream signaling partners. By targeting specific domains within Shc proteins that facilitate these interactions, the inhibitors disrupt the transmission of signals along their intended pathways. This interference can have profound effects on cellular behavior, as the perturbation of Shc-dependent signaling cascades may alter the fate of the cell and its responses to external cues. The development of Shc inhibitors represents a significant advancement in our understanding of intracellular communication networks and provides researchers with a valuable tool for investigating the intricate regulatory mechanisms governing cellular processes. Further research into the precise mechanisms by which Shc inhibitors modulate signaling events will undoubtedly contribute to the broader knowledge of cellular biology and may have implications in diverse areas of biological research and applications.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
Blocks MEK1/2 phosphorylation, interfering with MAPK/ERK signaling and influencing cell proliferation and differentiation. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Targets RAF kinases and receptors, disrupting pathways related to angiogenesis and cell proliferation. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
Inhibits MEK1/2, disrupting the MAPK pathway and potentially slowing cancer growth by affecting cell proliferation. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Specifically inhibits MEK1/2, disrupting the MAPK pathway and potentially inhibiting cancer cell proliferation. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Dual EGFR/HER2 inhibitor, disrupting downstream signaling pathways involved in cell growth and survival. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Targets SFKs, BCR-ABL, and other kinases, affecting pathways crucial for cell growth, proliferation, and survival. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Inhibits BCR-ABL and c-KIT tyrosine kinases, interfering with signaling pathways involved in cell proliferation. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
Targets BCR-ABL, inhibiting its activity and downstream signaling. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
EGFR tyrosine kinase inhibitor, blocking signaling pathways driving uncontrolled cell growth in specific cancers. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Selectively inhibits EGFR, disrupting downstream pathways associated with cell proliferation and survival. | ||||||